Radiopharmaceutical Market Size, Share, Growth, and Industry Analysis, By Type (Technetium-99, Gallium-67, Iodine-123, 18F, Rubidium-82, Yttrium-90, Lutetium-177), By Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Others), Regional Insights and Forecast to 2035
Radiopharmaceutical Market Overview
The global Radiopharmaceutical Market is projected to experience sustained growth from USD 10680.93 Million in 2026 to USD 31721.04 Million by 2035, exhibiting a CAGR of 12.86% during the forecast period 2026-2035.
The Radiopharmaceutical Market is witnessing significant expansion due to increasing cancer prevalence, growing adoption of nuclear medicine, rising demand for molecular imaging, and technological advancements in targeted radionuclide therapies. Radiopharmaceuticals are increasingly utilized across oncology, cardiology, neurology, and other medical specialties to support early disease detection, accurate diagnosis, treatment planning, and therapeutic monitoring. Technetium-99-based products represent an estimated 34% of the supplied product segmentation, reflecting the extensive use of technetium-based radiotracers in diagnostic imaging procedures. Healthcare providers are expanding their adoption of positron emission tomography, single-photon emission computed tomography, and targeted radioligand therapies to improve diagnostic accuracy and personalized treatment decisions. Growing investment in radioisotope production facilities, cyclotron infrastructure, radiopharmaceutical manufacturing capabilities, and specialized distribution networks is supporting market development. Advancements in 18F imaging compounds, Lutetium-177 therapeutic agents, and automated radiopharmaceutical synthesis technologies are creating additional opportunities for manufacturers. Increasing collaboration between pharmaceutical developers, nuclear medicine specialists, research institutions, and healthcare organizations is strengthening the development of innovative diagnostic and therapeutic products.
The United States Radiopharmaceutical Market is experiencing strong development due to advanced healthcare infrastructure, increasing utilization of nuclear imaging technologies, expanding oncology treatment programs, and growing clinical interest in precision medicine. North America is estimated to account for 42% of global market demand, supported by established nuclear medicine facilities, extensive diagnostic imaging networks, and increasing adoption of targeted radiopharmaceutical therapies. Hospitals and specialized diagnostic centers across the United States are investing in PET and SPECT imaging technologies, advanced radioisotope production systems, and radiopharmaceutical preparation capabilities. Rising demand for accurate cancer staging, cardiovascular evaluation, neurological disease assessment, and personalized therapeutic monitoring is encouraging wider clinical utilization. Companies are strengthening domestic isotope supply chains, expanding manufacturing capacity, and developing specialized distribution infrastructure to address the short shelf life and handling requirements of radioactive products. Continued research into targeted radionuclide treatments, improved imaging agents, and combination diagnostic-therapeutic approaches is expected to support further market development.
Key Findings
- Market Driver: Increasing cancer diagnosis and growing utilization of nuclear medicine are supporting radiopharmaceutical adoption, with an estimated 38% of demand growth influenced by expanding oncology imaging and targeted therapeutic applications.
- Major Market Restraint: Complex isotope production requirements, radioactive material handling regulations, and specialized transportation infrastructure create adoption barriers, with an estimated 24% of operational challenges associated with production capacity and supply-chain limitations.
- Emerging Trends: Targeted radioligand therapies and theranostic approaches are transforming nuclear medicine, with an estimated 28% of innovation activity focused on developing advanced therapeutic radiopharmaceuticals and precision oncology applications.
- Regional Leadership: North America is estimated to lead the Radiopharmaceutical Market with 42% share, supported by advanced nuclear medicine infrastructure, established pharmaceutical manufacturers, extensive diagnostic imaging capabilities, and increasing adoption of targeted cancer treatments.
- Competitive Landscape: Curium Pharma maintains a significant competitive position through isotope manufacturing, diagnostic radiopharmaceuticals, and distribution capabilities, while 30% of industry competitive initiatives focus on manufacturing expansion and targeted therapy innovation.
- Market Segmentation: Technetium-99 is estimated to lead the supplied product categories with 34% share, while Hospitals remain the leading application through extensive diagnostic imaging, nuclear medicine procedures, and therapeutic radiopharmaceutical administration.
- Recent Development: Radiopharmaceutical manufacturers are advancing isotope production, targeted delivery technologies, and oncology treatment platforms, with an estimated 25% of product development initiatives focused on improving therapeutic precision and clinical application capabilities.
Radiopharmaceutical Market Latest Trends
The Radiopharmaceutical Market is witnessing rapid technological advancement as pharmaceutical manufacturers and healthcare institutions increasingly integrate targeted radionuclide therapies, molecular imaging, and theranostic approaches into modern clinical practices. Approximately 28% of radiopharmaceutical innovation initiatives are estimated to focus on targeted therapies and precision oncology applications, reflecting growing interest in treatments that deliver radiation directly to selected disease-associated biological targets. Lutetium-177 is attracting increasing attention because of its role in targeted radioligand therapies, particularly for certain neuroendocrine tumors and prostate cancer. Manufacturers are expanding their research into specialized targeting molecules, improved radiolabeling processes, and more efficient isotope production technologies. The combination of diagnostic imaging and therapeutic radionuclides is also becoming increasingly important for selecting suitable patients and evaluating treatment response. Healthcare providers are investing in advanced PET and SPECT imaging infrastructure, radiopharmaceutical preparation facilities, and multidisciplinary nuclear medicine programs. These developments are strengthening the integration of molecular diagnostics with personalized cancer treatment while encouraging collaboration among pharmaceutical companies, healthcare institutions, and nuclear medicine specialists.
Radiopharmaceutical Market Dynamics
Driver
"Growing Cancer Burden and Increasing Adoption of Precision Nuclear Medicine"
The increasing burden of cancer and other chronic diseases is a major driver of the Radiopharmaceutical Market, encouraging healthcare providers to expand the use of advanced diagnostic imaging and targeted radionuclide treatments. An estimated 38% of demand growth is associated with oncology imaging and therapeutic applications, supported by the clinical need for earlier disease identification, accurate staging, and personalized treatment selection. Radiopharmaceuticals enable physicians to evaluate biological activity, identify disease-associated targets, and monitor therapeutic outcomes using specialized radioactive compounds. Technetium-99-based diagnostic agents continue to support nuclear medicine procedures, while 18F radiotracers are important for PET imaging in oncology and other medical specialties. Growing interest in Lutetium-177 therapies is also expanding the role of nuclear medicine beyond diagnosis into targeted cancer treatment. Healthcare institutions are developing specialized nuclear medicine departments and multidisciplinary oncology programs to support wider clinical adoption.
Restraint
"Complex Manufacturing Requirements and Radioisotope Supply Limitations Restrict Market Expansion"
The Radiopharmaceutical Market faces considerable restraints associated with complex radioisotope manufacturing, specialized infrastructure requirements, regulatory compliance, and limited product shelf life. An estimated 24% of operational challenges are associated with isotope production capacity, radioactive material handling, and supply-chain limitations. Radiopharmaceutical manufacturing requires controlled environments, specialized equipment, qualified personnel, radiation protection systems, and rigorous quality assurance procedures. Certain medical isotopes depend on nuclear reactors, cyclotrons, or specialized processing facilities, creating potential supply vulnerabilities when production infrastructure experiences maintenance interruptions or operational disruptions. Radioactive decay also places strict limitations on manufacturing schedules, transportation distances, and clinical administration timing. These factors can increase operational complexity and restrict product accessibility in regions without established nuclear medicine infrastructure. Manufacturers are responding by developing more reliable production networks, improving regional distribution capabilities, and exploring alternative isotope manufacturing approaches.
Opportunity
"Expansion of Targeted Radioligand Therapies Creates New Opportunities in Precision Oncology"
The growing adoption of precision oncology is creating substantial opportunities for radiopharmaceutical manufacturers developing targeted diagnostic and therapeutic products. An estimated 35% of emerging growth opportunities are associated with radioligand therapies, theranostic applications, and advanced molecular imaging technologies. Lutetium-177-based therapies have demonstrated the potential of delivering therapeutic radiation through molecules designed to recognize particular disease-associated targets. This approach is encouraging research into additional cancer indications, improved targeting agents, and new combinations of diagnostic and therapeutic radionuclides. Pharmaceutical developers are investing in radiopharmaceutical pipelines that support patient selection through molecular imaging and subsequent targeted treatment where clinically appropriate. Opportunities are also expanding in radiochemistry development, clinical research partnerships, specialized treatment centers, and manufacturing services. Growing demand for individualized cancer management is encouraging healthcare providers to strengthen capabilities for administering and monitoring targeted radionuclide therapies.
Challenge
"Maintaining Reliable Isotope Availability and Specialized Clinical Capabilities Remains Challenging"
The Radiopharmaceutical Market continues to face challenges related to isotope supply reliability, radioactive material transportation, clinical workforce availability, and complex treatment delivery requirements. An estimated 27% of industry operational improvement initiatives are focused on strengthening supply continuity, manufacturing coordination, and specialized distribution capabilities. Diagnostic isotopes and therapeutic radionuclides have different physical properties, production requirements, and handling procedures, making consistent supply management technically demanding. Manufacturing delays, limited transport infrastructure, or disruptions at specialized isotope facilities can affect scheduled diagnostic procedures and treatment administration. Healthcare providers must coordinate radiopharmaceutical delivery with patient appointments, equipment availability, and clinical preparation requirements to minimize waste and maintain treatment schedules. Companies are developing diversified isotope supply arrangements, automated production systems, and regional distribution partnerships to reduce operational vulnerability and improve dependable access.
Radiopharmaceutical Market Segmentation
By Type
Technetium-99: Technetium-99-based radiopharmaceuticals represent an estimated 34% of the supplied product segmentation. In clinical practice, the metastable form, technetium-99m, is widely used for SPECT imaging because of its favorable imaging characteristics and established clinical applications. Hospitals and diagnostic centers utilize technetium-labeled compounds for evaluating cardiovascular function, skeletal abnormalities, renal function, and several other medical conditions. Its extensive clinical history and compatibility with established imaging equipment support continued utilization across healthcare systems.
Gallium-67: Gallium-67 represents an estimated 6% of the supplied market segmentation and continues to serve selected nuclear medicine applications involving infection, inflammation, and tumor-related imaging. Although newer PET radiotracers have displaced some traditional gallium-based examinations, Gallium-67 remains relevant where specific clinical indications and established imaging protocols support its use. Healthcare institutions utilize the isotope in specialized diagnostic procedures requiring evaluation of biological activity and disease distribution.
Iodine-123: Iodine-123 accounts for an estimated 9% of the supplied product segmentation and remains important in selected thyroid, neurological, and specialized functional imaging procedures. Its radioactive characteristics support diagnostic applications involving iodine-based biological processes and specific molecular targets. Hospitals and nuclear medicine departments use Iodine-123 radiopharmaceuticals for examining thyroid function and supporting certain neurological investigations. Demand is influenced by clinical guidelines, imaging equipment availability, and the need for accurate disease characterization.
18F: Fluorine-18-based radiopharmaceuticals contribute an estimated 25% of the supplied product segmentation, supported by widespread adoption of PET imaging in oncology, neurology, and cardiology. The isotope is used in important diagnostic tracers that allow clinicians to evaluate metabolic and molecular activity. Increasing demand for cancer staging, treatment response assessment, and disease characterization is supporting utilization across hospitals and specialized diagnostic centers. The expanding role of precision medicine is encouraging development of new 18F-labeled imaging agents targeting specific biological pathways.
Rubidium-82: Rubidium-82 represents an estimated 5% of the supplied product segmentation and is primarily associated with PET myocardial perfusion imaging. The isotope enables assessment of blood flow to heart tissue, supporting evaluation of coronary artery disease and selected cardiovascular conditions. Its short half-life makes generator-based availability particularly important for clinical operations. Specialized cardiac imaging centers and hospitals with PET capabilities represent the principal users of Rubidium-82 diagnostic products.
Yttrium-90: Yttrium-90 contributes an estimated 8% of the supplied product segmentation and is widely recognized for therapeutic applications involving localized radiation delivery. Yttrium-90 microsphere treatment is used in selected liver malignancies, providing a targeted approach that delivers radiation to diseased tissue through specialized administration procedures. Its therapeutic characteristics make the isotope relevant to interventional oncology and multidisciplinary cancer treatment programs. Adoption depends on appropriate patient selection, specialized clinical infrastructure, and coordinated treatment planning.Manufacturers are improving treatment preparation, isotope handling, dosimetry, and delivery technologies to support safer and more consistent therapeutic administration. Hospitals implementing Yttrium-90 programs require collaboration among nuclear medicine specialists, interventional radiologists, oncologists, and medical physicists. Continued research into treatment optimization and patient selection is expected to support its role within specialized oncology services.
Lutetium-177: Lutetium-177 represents an estimated 13% of the supplied product segmentation and is becoming increasingly important in targeted radioligand therapy. It is utilized in approved treatments for selected neuroendocrine tumors and prostate cancer, demonstrating the clinical potential of delivering therapeutic radiation through molecules that bind to specific biological targets. Growing interest in theranostics is encouraging pharmaceutical developers to investigate additional treatment indications and combinations with molecular imaging technologies.Manufacturers are expanding investment in Lutetium-177 isotope production, radiopharmaceutical labeling, clinical development, and specialized manufacturing facilities. Healthcare institutions are strengthening targeted radionuclide therapy programs to accommodate growing clinical utilization. Continued advances in radiochemistry, treatment planning, and molecular targeting are expected to support further development of Lutetium-177 products while increasing demand for reliable isotope supply and qualified treatment facilities.
By Application
Hospitals: Hospitals represent an estimated 55% of the Radiopharmaceutical Market application demand.Hospitals utilize radiopharmaceuticals for diagnostic imaging, disease staging, functional assessment, targeted radionuclide therapy, and monitoring treatment response. Large healthcare institutions frequently maintain dedicated nuclear medicine departments equipped with SPECT, PET, and hybrid imaging technologies. The increasing integration of nuclear medicine with oncology, cardiology, and neurological care is encouraging investment in advanced radiopharmaceutical services.
Ambulatory Surgical Centers: Ambulatory Surgical Centers account for an estimated 12% of the supplied application segmentation. Their participation is primarily associated with selected outpatient procedures, coordinated specialty care, and diagnostic services provided through associated healthcare networks. Radiopharmaceutical utilization in these settings depends on local licensing, equipment availability, clinical requirements, and relationships with specialized nuclear medicine providers. Demand is influenced by broader healthcare efforts to improve outpatient access and reduce unnecessary hospital-based treatment.
Diagnostic Centers: Diagnostic Centers contribute an estimated 27% of the supplied application segmentation and are important providers of molecular imaging services. Specialized facilities utilize PET and SPECT imaging technologies to support cancer diagnosis, cardiovascular assessment, neurological evaluation, and treatment monitoring. Increasing demand for early disease detection and more precise diagnostic information is encouraging the development of dedicated nuclear medicine imaging centers.
Others: Other applications represent an estimated 6% of the supplied market segmentation and include specialized research institutions, academic medical organizations, and additional healthcare facilities utilizing radiopharmaceutical products. These organizations contribute to clinical research, diagnostic technology evaluation, radiochemistry development, and investigation of new targeted treatment approaches. Their activities support innovation across both diagnostic and therapeutic nuclear medicine.
Radiopharmaceutical Market Regional Outlook
North America
North America is estimated to hold 42% of the Radiopharmaceutical Market, supported by advanced healthcare infrastructure, established nuclear medicine facilities, strong pharmaceutical research capabilities, and growing adoption of targeted radionuclide therapies. The United States represents the principal regional contributor through extensive oncology services, molecular imaging networks, specialized diagnostic facilities, and clinical research activities. Increasing utilization of PET and SPECT imaging is supporting demand for Technetium-99-based and 18F radiopharmaceuticals.
Europe
Europe represents an estimated 28% of global Radiopharmaceutical Market demand, supported by established nuclear medicine research institutions, advanced hospital systems, pharmaceutical manufacturing capabilities, and increasing use of targeted radionuclide therapies. Germany, France, the United Kingdom, Italy, and other developed healthcare markets contribute to regional demand through oncology imaging, cardiovascular diagnostics, and specialized nuclear medicine procedures.
Asia-Pacific
Asia-Pacific accounts for an estimated 22% of the Radiopharmaceutical Market, supported by expanding healthcare infrastructure, growing cancer diagnosis requirements, increasing nuclear medicine adoption, and investment in advanced diagnostic technologies. China, Japan, India, South Korea, and Australia represent important markets as hospitals and diagnostic centers strengthen molecular imaging and specialized oncology capabilities. Rising healthcare investment is improving access to PET and SPECT procedures.
Middle East and Africa
The Middle East and Africa region represents an estimated 5% of global Radiopharmaceutical Market demand, supported by developing nuclear medicine infrastructure, growing investment in specialized hospitals, and increasing focus on advanced cancer diagnosis. Countries in the Gulf region are expanding access to modern diagnostic imaging and oncology services, while selected African healthcare markets are gradually strengthening nuclear medicine capabilities.Regional development is influenced by access to qualified clinical personnel, radiopharmaceutical transportation infrastructure, and specialized medical equipment. Healthcare organizations are exploring partnerships with international manufacturers and isotope suppliers to improve product availability. Investments in cancer treatment facilities and modern diagnostic services are expected to create opportunities, although infrastructure limitations continue to affect adoption across developing healthcare systems.
Rest of the World
Rest of the World contributes an estimated 3% of global Radiopharmaceutical Market demand, including selected markets across Latin America and smaller developing healthcare economies. Regional demand is influenced by expanding diagnostic imaging capabilities, improving oncology treatment access, and increasing awareness of nuclear medicine applications. Hospitals and specialized diagnostic facilities are gradually investing in molecular imaging technologies to support more accurate disease assessment.
List of Top Radiopharmaceutical Market Companies
- Advanced Accelerator Applications SA
- Alpha Tau Medical Ltd.
- Bayer AG
- Blue Earth Diagnostics Limited
- Bracco Diagnostics, Inc
- Cardinal Health, Inc
- Clarity Pharmaceuticals
- Curium Pharma
- Eckert & Ziegler Group
- Eczacibasi-Monrol
- GE Healthcare
- Ion Beam Applications SA (IBA)
- Lantheus Medical Imaging, Inc
- Life Molecular Imaging GmbH
- NTP Radioisotopes SOC Ltd
- Orano Med
- Siemens Healthineers
- Telix Pharmaceuticals Limited
Top Two Companies with Highest Market Share
- Curium Pharma: Curium Pharma maintains a significant competitive presence through its diagnostic radiopharmaceutical portfolio, isotope manufacturing capabilities, specialized nuclear medicine expertise, and international distribution infrastructure. The company has 30% strengthened its position through product development, manufacturing investment, and strategic transactions.
- Lantheus Medical Imaging, Inc: Lantheus maintains a strong 15% position in diagnostic radiopharmaceuticals through molecular imaging products, particularly in prostate cancer imaging. Its competitive capabilities include commercial distribution, clinical development, and partnerships supporting precision medicine.
Investment Analysis and Opportunities
The Radiopharmaceutical Market is attracting investment as pharmaceutical companies and healthcare organizations expand their focus on molecular imaging, targeted radionuclide therapy, and precision oncology. An estimated 35% of emerging investment opportunities are associated with therapeutic radiopharmaceutical development, clinical research, and specialized isotope manufacturing capabilities. Growing interest in Lutetium-177 therapies is encouraging manufacturers to establish reliable isotope supply arrangements, advanced radiochemistry facilities, and scalable pharmaceutical production systems. Investment opportunities extend across cyclotron development, automated synthesis technology, radiopharmaceutical quality assurance, specialized transportation networks, and nuclear medicine treatment infrastructure. Healthcare providers are strengthening their diagnostic and therapeutic capabilities to support more personalized cancer management. Partnerships between pharmaceutical manufacturers, isotope suppliers, research institutions, and hospitals are becoming increasingly important for accelerating product development and improving clinical accessibility.
New Product Development
New product development in the Radiopharmaceutical Market is increasingly focused on targeted radionuclide therapies, improved molecular imaging agents, and more efficient radiopharmaceutical manufacturing technologies. An estimated 25% of product development initiatives are directed toward improving therapeutic targeting, radiolabeling precision, and clinical application capabilities. Manufacturers are developing specialized compounds designed to recognize biological targets associated with cancer and other diseases, enabling more selective diagnostic imaging and therapeutic radiation delivery. Lutetium-177-based radioligand therapies remain an important area of pharmaceutical innovation, while 18F-based radiotracers continue to support advances in PET imaging. Companies are improving radiochemical synthesis methods, purification technologies, isotope stability management, and automated production systems to strengthen product consistency. Development programs are also emphasizing improved patient selection, clinical dosimetry, safety evaluation, and integration with molecular imaging technologies.Manufacturers are also expanding development of radiopharmaceutical production systems and emerging therapeutic isotope platforms.Product innovation increasingly involves development of new targeting molecules, improved PET tracers, more efficient radiopharmaceutical preparation systems, and manufacturing technologies capable of supporting growing clinical demand. Research into targeted alpha therapies is creating additional development opportunities alongside established diagnostic and therapeutic radionuclides. These advances are encouraging collaboration between isotope producers, pharmaceutical developers, nuclear medicine professionals, and healthcare providers to improve the availability and clinical application of next-generation radiopharmaceutical technologies.
Five Recent Developments
- February 2026 – Eckert & Ziegler Expands Therapeutic Development Partnerships:Eckert & Ziegler Group announced a partnership with Molecular Partners to support development of radiolabeled DARPin therapeutic candidates. The collaboration extends its participation in emerging targeted radionuclide therapy platforms.
- May 2026 – Orano Med Opens Scientific Excellence Center: Orano Med inaugurated its headquarters and Scientific Excellence Center in Villejuif, France, strengthening its research infrastructure for targeted alpha therapies and supporting development of specialized cancer treatment technologies.
- August 2026 – Lantheus Announces Major Industry Combination Agreement: Lantheus Medical Imaging, Inc announced a definitive agreement to combine with Curium Pharma through an acquisition transaction. The proposed combination is intended to bring together complementary diagnostic and therapeutic radiopharmaceutical portfolios, manufacturing capabilities, and commercial infrastructure.
- September 2026 – Telix Advances Specialized Brain Cancer Imaging: Telix Pharmaceuticals Limited received U.S. regulatory approval for Pixclara, a Fluorine-18-based imaging product for glioma evaluation, and initiated commercial availability. The development expands specialized molecular imaging options for brain cancer assessment.
- October 2026 – GE Healthcare Strengthens Radiopharmaceutical Supply Infrastructure: GE Healthcare announced an agreement to acquire SOFIE Biosciences to expand its U.S. PET radiopharmaceutical manufacturing and distribution capabilities. The proposed acquisition supports broader access to specialized imaging tracers and strengthens the company's involvement in nuclear medicine supply networks.
Future Outlook
The Radiopharmaceutical Market is expected to experience continued development as healthcare providers increasingly integrate molecular imaging, precision oncology, and targeted radionuclide therapies into clinical practice. Growing demand for accurate disease diagnosis, improved treatment selection, and personalized therapeutic approaches will encourage investment in advanced PET and SPECT imaging systems, specialized radiopharmaceutical preparation facilities, and clinical nuclear medicine services. Technetium-99-based diagnostic products are expected to remain important in established imaging applications, while 18F radiotracers will continue supporting molecular imaging development. Lutetium-177 therapies are likely to attract significant research attention as manufacturers investigate additional clinical applications and refine targeted radioligand treatment approaches. Increasing collaboration between pharmaceutical developers, research organizations, isotope suppliers, and healthcare institutions will support innovation in radiochemistry, clinical evaluation, and manufacturing technologies. Expanding healthcare infrastructure and improved access to nuclear medicine services may create additional opportunities across developing markets.
Radiopharmaceutical Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 10680.93 Million in 2026 |
|
|
Market Size Value By |
USD 31721.04 Million by 2035 |
|
|
Growth Rate |
CAGR of 12.86% from 2026-2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Frequently Asked Questions
The global Radiopharmaceutical Market is expected to reach USD 31721.04 Million by 2035.
The Radiopharmaceutical Market is expected to exhibit a CAGR of 12.86% by 2035.
Advanced Accelerator Applications SA, Alpha Tau Medical Ltd., Bayer AG, Blue Earth Diagnostics Limited, Bracco Diagnostics, Inc, Cardinal Health, Inc, Clarity Pharmaceuticals, Curium Pharma, Eckert & Ziegler Group, Eczacibasi-Monrol, GE Healthcare, Ion Beam Applications SA (IBA), Lantheus Medical Imaging, Inc, Life Molecular Imaging GmbH, NTP Radioisotopes SOC Ltd, Orano Med, Siemens Healthineers, Telix Pharmaceuticals Limited
In 2026, the Radiopharmaceutical Market value will reach at USD 10680.93 Million.